Journal
ACS INFECTIOUS DISEASES
Volume 6, Issue 5, Pages 909-915Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acsinfecdis.0c00052
Keywords
niclosamide; broad antiviral agents; coronavirus; SARS-CoV; MERS-CoV; SARS-CoV-2 (COVID-19); flavivirus; Zika virus; Ebola virus; human adenovirus
Categories
Funding
- National Institute of Allergy and Infectious Diseases (NIAID) [R01 AI131669, R21 AI134568]
- National Institutes of Health
- John D. Stobo, the M. D. Distinguished Chair Endowment Fund
- John Sealy Memorial Endowment Fund at UTMB
- NIH [AI142759, AI127744, AI136126]
- Kleberg Foundation
- John S. Dunn Foundation
- Amon G. Carter Foundation
- Gilson Longenbaugh Foundation
- Summerfield Robert Foundation
Ask authors/readers for more resources
The recent outbreak of coronavirus disease 2019 (COVID-19) highlights an urgent need for therapeutics. Through a series of drug repurposing screening campaigns, niclosamide, an FDA-approved anthelminthic drug, was found to be effective against various viral infections with nanomolar to micromolar potency such as SARS-CoV, MERS-CoV, ZIKV, HCV, and human adenovirus, indicating its potential as an antiviral agent. In this brief review, we summarize the broad antiviral activity of niclosamide and highlight its potential clinical use in the treatment of COVID-19.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
